Regulatory innovation and drug development for early-stage Alzheimer's disease.
about
Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical ADCervical spinal cord injury: tailoring clinical trial endpoints to reflect meaningful functional improvementsAdvances in Alzheimer's disease drug developmentAlzheimer's disease: new data highlight nonneuronal cell types and the necessity for presymptomatic prevention strategiesCerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker TeamTaurine in drinking water recovers learning and memory in the adult APP/PS1 mouse model of Alzheimer's diseaseCognitive training-induced short-term functional and long-term structural plastic change is related to gains in global cognition in healthy older adults: a pilot study.The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's diseaseIron accumulation in the basal ganglia in Huntington's disease: cross-sectional data from the IMAGE-HD study.After disappointments, Alzheimer's researchers seek out new paths: biomarkers and combination therapies may lead to disease-modifying treatments, experts say.The A4 study: stopping AD before symptoms begin?Performance on a pattern separation task by Alzheimer's patients shows possible links between disrupted dentate gyrus activity and apolipoprotein E ∈4 status and cerebrospinal fluid amyloid-β42 levels.Regional cortical thinning and cerebrospinal biomarkers predict worsening daily functioning across the Alzheimer's disease spectrum.Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014The preclinical Alzheimer cognitive composite: measuring amyloid-related declineAssessment of Age-Related Differences in Functional Capacity Using the Virtual Reality Functional Capacity Assessment Tool (VRFCAT)Unbiased approaches to biomarker discovery in neurodegenerative diseasesPro: Are we ready to translate Alzheimer's disease modifying therapies to people with Down syndrome?Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function InstrumentFunctional Activities Questionnaire Items that Best Discriminate and Predict Progression from Clinically Normal to Mild Cognitive ImpairmentDiffusion imaging changes in grey matter in Alzheimer's disease: a potential marker of early neurodegeneration.Do firms underinvest in long-term research? Evidence from cancer clinical trialsThe Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target PopulationsA quantitative neural network approach to understanding aging phenotypesThe Traumatic Brain Injury Endpoints Development (TED) Initiative: Progress on a Public-Private Regulatory Collaboration to Accelerate Diagnosis and Treatment of Traumatic Brain Injury.The Harvard Automated Phone Task: new performance-based activities of daily living tests for early Alzheimer's disease.Recent Developments in Understanding Brain Aging: Implications for Alzheimer's Disease and Vascular Cognitive Impairment.Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trials.Function and clinical meaningfulness of treatments for mild Alzheimer's disease.Progress in Alzheimer's disease research circa 2013: Is the glass half empty or half full?Identification of potential or preclinical cognitive impairment and the implications of sophisticated screening with biomarkers and cognitive testing: does it really matter?Multilocus genetic profiling to empower drug trials and predict brain atrophy.Choosing Alzheimer's disease prevention clinical trial populations.Presymptomatic cortical thinning in familial Alzheimer disease: A longitudinal MRI study.The role and therapeutic targeting of α-, β- and γ-secretase in Alzheimer's diseaseA new regulatory road-map for Alzheimer's disease drug developmentA Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer's Disease.Detection of Conversion from Mild Cognitive Impairment to Alzheimer's Disease Using Longitudinal Brain MRI.Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward.
P2860
Q26801629-A33509CD-DA60-47BD-9017-9F2F39D8BE9AQ26801666-6524FC7F-C604-4252-AE92-EF2740D3F462Q26823368-E0F5FCC6-671E-4542-B910-841EC4DE9BA0Q26849352-E4D45FC1-3248-45B3-8111-4D115FE46CB3Q26852851-7904CA42-C64C-4D68-9D16-982E311D12E9Q28595520-E22854DD-212A-4CD3-B5FD-8746A84BE34FQ28649926-BB760B29-40FB-4CA3-9480-9D9BCA21DD4CQ30625798-E9DCA15A-7F32-47AF-AEE7-9E6B128DBB03Q30736054-E54E2778-896E-4068-BF32-F5791F985343Q30946340-ED2A979F-9E9C-419B-B25B-6593C939F4F7Q33642389-D867A891-2E41-4838-B60E-8119F6FC2D49Q33725775-9DE54D9D-B1DB-48CB-A150-BFC1506C5885Q33745951-A65DE4D3-BC0C-494D-B8B6-3AF56BD916F5Q33953180-6F7575F4-6128-4DD4-AEB8-F55D7A1964DCQ34408888-7D481440-4025-4024-BAD8-CB04FC720AC2Q34422469-96012F1B-8188-408B-9914-520497684CC7Q34503458-DF7DA4A6-F0A9-4C40-9C57-DA8F25592569Q34625918-4E907D0C-DDB0-4F8C-A516-4E6BDB15149EQ34630583-399876E9-FF9D-439D-8733-283409122686Q35418054-1DFC21D5-80A6-458B-BCE1-C57B2A8C7D1FQ35662685-2F9FAA37-2007-44B0-9E2B-A8901249202FQ35806043-14CBC093-5903-4C2C-9174-DBEDF9D719AEQ36020575-E050E786-77F5-49E0-BD75-37C562DE85F0Q36165011-24C2DF07-EAC0-4A16-AABF-6DDA949E6936Q36218542-C2C76751-4F36-4DCB-A454-8DDB8A20F879Q36330425-B5BD6FEE-64AF-499B-8CE7-F401CDCDE31AQ36351683-D2266CDF-B35A-4325-B162-05A6E3BA545DQ36853502-A4C8929A-E1AA-4F41-AA68-E3CCED2BA62CQ36926750-999E69BA-A236-4B17-BF2E-A4B86F280D15Q36934148-D4113F2D-27BF-42C4-9D34-9E3D8D672B13Q36997889-5FD1823D-336C-4EA0-9812-9CA43F0693A1Q37043996-4E7FE826-774D-4487-A06F-EDB1726E0472Q37184374-962B6659-32EC-4B90-83DE-8A0668B766DFQ37395823-F839E861-BA12-4D29-9092-1EED1029A301Q37415094-8CB33872-B379-423C-87B2-512C14F0734CQ37474466-7346C3D6-F50C-47B7-BE30-DEEEEF18D2C2Q37510270-43394803-CDA4-4FC9-933B-3A145FB41A52Q37590389-86CAC3D6-E519-44D4-A47A-61792F9B1B98Q37662557-E221DFD8-0F66-4580-91EE-330D840C934EQ37670673-1542BFF7-53E4-4725-80F1-4605319B1432
P2860
Regulatory innovation and drug development for early-stage Alzheimer's disease.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Regulatory innovation and drug development for early-stage Alzheimer's disease.
@en
Regulatory innovation and drug development for early-stage Alzheimer's disease.
@nl
type
label
Regulatory innovation and drug development for early-stage Alzheimer's disease.
@en
Regulatory innovation and drug development for early-stage Alzheimer's disease.
@nl
prefLabel
Regulatory innovation and drug development for early-stage Alzheimer's disease.
@en
Regulatory innovation and drug development for early-stage Alzheimer's disease.
@nl
P356
P1476
Regulatory innovation and drug development for early-stage Alzheimer's disease.
@en
P2093
Nicholas Kozauer
Russell Katz
P304
P356
10.1056/NEJMP1302513
P407
P577
2013-03-13T00:00:00Z